FDA should reassess postmarket trials for cancer drugs approved via accelerated pathway, researchers say

The FDA may need to reassess how confirmatory trials are conducted after just one-fifth of such trials for cancer drug indications approved via the FDA’s accelerated approval pathway have demonstrated improvements in overall survival (OS), researchers reported Tuesday in JAMA Internal Medicine research.